Product Data Sheet

Pyributicarb

Cat. No.: HY-111202 CAS No.: 88678-67-5 Molecular Formula: $C_{18}H_{22}N_2O_2S$ Molecular Weight: 330.44

Target: Cytochrome P450

Pathway: Metabolic Enzyme/Protease

Powder

3 years 4°C 2 years

In solvent -80°C 2 years -20°C 1 year

-20°C

SOLVENT & SOLUBILITY

In Vitro

Storage:

DMSO: 100 mg/mL (302.63 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.0263 mL	15.1313 mL	30.2627 mL
	5 mM	0.6053 mL	3.0263 mL	6.0525 mL
	10 mM	0.3026 mL	1.5131 mL	3.0263 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.57 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (7.57 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.57 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Pyributicarb, a carbamate-type herbicide, is a potent activator of both CYP3A4 gene and human pregnane X receptor (hPXR).
IC ₅₀ & Target	CYP3A4 ^[1] , hPXR ^[2]
In Vitro	Pyributicarb, a carbamate-type herbicide, is a potent activator of both CYP3A4 gene and human pregnane X receptor (hPXR). Pyributicarb is found to increase the CYP3A4 reporter activity at 0.1 to 1 μM more strongly than typical CYP3A4 inducer rifampicin. Expression of hPXR-siRNA clearly diminishes the Pyributicarb-stimulated CYP3A4 reporter activity in 3-1-10 cells

	and decreases the endogenous CYP3A4 mRNA levels in HepG2 cells ^[1] . Pyributicarb induces luciferase transcription via hPXR at low concentrations in the order of 10 nM. The relative potency of Pyributicarb for hPXR is 8.6-fold that of rifampicin (RIF) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Pyributicarb causes enhancement of CYP3A4-derived reporter activity in mouse livers introduced with hPXR by adenovirus $^{[1]}$.
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay [1]

HepG2-derived cells stably expressing the CYP3A4 reporter gene (3-1-10 cells) are used in this experiment. The cells are treated with 0.3 to 30 μ M Pyributicarb for 48 h. Then reporter activities are determined^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal
Administration [1]

Male ICR mice (5 weeks old) are used and fed standard rodent chow. After 18-h fasting, mice are injected i.v. with adenovirus $[4.0 \times 10^9 \, 50\%$ titer culture infectious dose (TCID₅₀)/mouse]. Three days after the infection, vehicle (0.5% methyl cellulose/saline) or Pyributicarb (100 mg/kg/day) is administered p.o. for 2 consecutive days. Animals are killed 20 h after the last dose^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Matsubara T, et al. Assessment of human pregnane X receptor involvement in pesticide-mediated activation of CYP3A4 gene. Drug Metab Dispos. 2007 May;35(5):728-33.

[2]. Kojima H, et al. Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using in vitro reporter gene assays. Toxicology. 2011 Feb 27;280(3):77-87.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA